Newborn screening for spinal muscular atrophy (SMA) has changed the diagnostic paradigm for children with the condition, yet delays in implementation are causing inequities within the SMA community. A unified global approach is needed to implement screening and mitigate the barriers in access to high-cost treatments.
Access to this article via Institution of Civil Engineers Library is not available. Bishop, H.
Jesy Nelson provides emotional update on twins’ rare genetic condition. The Independent https://www.independent.co.uk/bulletin/culture/jesy-nelson-twins-sma-update-b2911412.html (31 January 2026).
Strauss, K. A.
et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
Nat. Med.
28 , 1381–1389 (2022). Kariyawasam, D.
S. et al.
Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child Adolesc.
Health 7 , 159–170 (2023). Shih, S.
T. F.
et al. Modelling the cost-effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency.
Int. J.
Neonatal Screen. 8 , 45 (2022).
Kariyawasam, D. S.
T., Russell, J. S., Wiley, V., Alexander, I.
Nature Reviews Neurology published a clinical update in Neurology on 07 May 2026.
The item focuses on Newborn screening for spinal muscular atrophy: time is motor neuron.
Review the original article for the full source wording and details.